Halyna Mostbauer

Halyna Mostbauer

Auto-generated profile, based on publicly available information

Halyna Mostbauer

Bogomolets National Medical University, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Rheumatology
Verified
Journal Article
Open access
MDMarta Dzhus
Marta Dzhus
HMHalyna Mostbauer
Halyna Mostbauer
Introduction: Takayasu arteritis (TAK) is a granulomatous inflammation of vessels of large diameter, mainly affecting the aorta and its proximal branches, which is more common in young women. The incidence of coronary artery disease in TAK is unknown and not sufficiently studied.Material and Methods: A literature review was performed for the period 2003 to 2023 using a search of the PubMed and Scopus scientific databases. We used the following key words to search the academic journal data-bases: “Takayasu arteritis”, “coronary angiography”, “myocardial revascularization”, “coronary artery disease”, “angina pectoris”, and “myocardial infarction”.Results: The analysis of studies showed that coronary artery lesions (CAL) in TAK are not uncommon, being identified particularly in children and young individuals. Pathology of the coronary arteries increases the morbidity and mortality of TAK patients. In TAK, the ostia and proximal segments of the coronary arteries are more frequently affected, presenting as stenosis or occlusion with the development of stable coronary artery disease, unstable coronary artery disease, acute myocardial infarction, and sudden death. The diagnosis of TAK and coronary artery pathology is often complicated due to non-specific manifestations and frequently the absence of symptoms. The treatment of patients with TAK with CAL is challenging and requires both pharmacological therapy and interventional or surgical methods of myocardial revascularization.Conclusions: Takayasu arteritis is a more prevalent cause of CAL development, especially in young patients, than previously believed, and cardiovascular death due to CAL is not rare. Early diagnosis of TAK with CAL, particularly occlusion or hemodynamically significant stenosis, and the prompt initiation of appropriate treatment prevent dangerous complications, reduce mortality, and improve prognosis.

30 December 2022 in Rheumatology
Verified
Journal Article
Closed access
MDMarta Dzhus
Marta Dzhus
HMHalyna Mostbauer
Halyna Mostbauer
Introduction: Giant cell arteritis (GCA) is a systemic vasculitis that affects large vessels. Cardiovascular complications that develop with GCA have high morbidity and can be fatal. The aim of this work was to discuss epidemiology, clinical picture, etiopathology and risk of development of cardiovascular complications in GCA.Material and Methods: A literature review was performed for 2002 to 2021 using PubMed and Medline scientific search databases. The following keywords were used to search academic journal databases: “giant cell arteritis”, “heart attack”, “cardiovascular system”, “aortic aneurysm”, “coronary heart disease”, “aortic dissection”, “myocardium” and “stroke”. Articles written in languages, other than English, were excluded.Results: The analysis of studies showed an increased risk of an aneurysm, aortic dissection, coronary heart disease, cerebrovascular events, and peripheral artery disease in patients with GCA. This was not surprising as it has been shown that, cardiovascular complications worsens the prognosis in GCA. According to the results of observations and cited studies the most significant risk of cardiovascular complications was observed in the first year following the diagnosis of GCA.Conclusions: Patients with GCA have an increased risk of cardiovascular disease, but research data/findings are somewhat conflicting, and there is limited information/knowledge on how to treat the patients. Awareness of the risk of cardiovascular disease in GCA is essential, and monitoring these potentially fatal consequences is mandatory in patients with GCA. It is critical to be aware of the danger of cardiovascular illness in GCA patients and to keep track of these potentially deadly outcomes.

29 December 2022 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
MDMarta Dzhus
Marta Dzhus
MKM.S. Kulyk
M.S. Kulyk
TKT.A. Karasevska
T.A. Karasevska
HMH.V. Mostbauer
H.V. Mostbauer
OIO.I. Ivashkivskyi
O.I. Ivashkivskyi
HNH.L. Novytska
H.L. Novytska
Sarcopenia is characterized by a loss of skeletal muscle mass, a decrease in muscle strength and/or physical performance, and is one of the main causes for limiting daily activities in the elderly. This is associated with an increased incidence of many adverse events such as dysfunction, falls, frailty, hospitalization, disability, and mortality. Primary (considered as a part of the aging process) and secondary sarcopenia (due to malabsorption, immobility/bed rest, starvation, hypothyroidism, osteoporosis, immune-mediated rheumatic diseases) are united by a chronic inflammatory process of different degrees. Sarcopenia supports one of the most widely accepted theories that low-grade chronic inflammation is important in the pathogenesis of many diseases. For a long time, sarcopenia was considered an age-related disease, but recently it has been reported to be more common in young subjects with autoimmune diseases. In particular, the relationship between sarcopenia and rheumatic diseases such as rheumatoid arthritis has been studied in detail. Although the pathogenesis of sarcopenia in autoimmune diseases is not fully understood, it is believed that a chronic inflammatory process contributes to the development of loss of muscle mass and strength, and is different depending on the underlying disease. The definition of sarcopenia varies between studies, which complicates and limits direct comparisons. Therefore, in this review, we demonstrate various diagnostic criteria for sarcopenia, focusing on its prevalence in patients with rheumatic diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, axial spondylitis, psoriatic arthritis, and systemic sclerosis. We developed a structured search strategy for English language publications in PubMed using the term “sarcopenia” in combination with the following keywords: “inflammation”, “diagnosis”, “criteria”, “muscle mass”, “strength”, “outcomes”, “disability”, “mortality”, “pathophysiology”, “rheumatoid arthritis”, “juvenile arthritis”, “axial spondylitis”, “psoriatic arthritis”, “systemic sclerosis”. We focused on clinical trials, meta-analyses and review articles. Articles published only after 2000 year were included, however, we did not include major contributions published before. The search was completed on October 8, 2022.

30 June 2022 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
ONO.I. Nishkumay
O.I. Nishkumay
HMH.V. Mostbauer
H.V. Mostbauer
OAO.O. Alekseenko
O.O. Alekseenko
KMK.I. Moskalenko
K.I. Moskalenko
PLP.O. Lazarev
P.O. Lazarev
MSM.I. Shevchuk
M.I. Shevchuk
Introduction. The problem of cardiovascular morbidity and mortality remains an urgent issue of modern medicine, and arterial stiffness is its independent predictor. Lively discussions about the correct approach to the prevention and treatment of comorbid conditions – increased vascular stiffness as an influential factor of the cardiovascular events and decreased bone mineral density (osteoporosis), primarily arise against the background of the need and safety of calcium and vitamin D supplements. The purpose was to search for literature data as for possible common pathogenetic links in the progression of arterial stiffness and the development of osteoporosis in order to assess the safety of the use of drugs to prevent osteoporotic fractures. Results. Analysis of literature sourses had showed that possible osteogenic factors affecting arterial stiffness may be: secondary hyperparathyroidism, disbalance of the RANK/RANKL/OPG system, inhibition of vitamin K-dependent matrix proteins (Gla-protein), osteopontin, etc. Conclusions. Today, there are many hypotheses confirming the possible influence of osteogenic factors on vascular stiffness and arterial calcification. Therefore, the search for sensitive markers and the development of screening protocols for the patients with risk factors for both osteoporosis and vascular changes are extremely relevant. A special issue is the possibility of using monotherapy for these comorbid pathologies, which can safely and efficiently influence the prevention of complications – both low-energy osteoporotic fractures and cardiovascular catastrophes. This will be the focus of our further research.

26 June 2024 in Ukrainian Therapeutical Journal
Verified
Journal Article
Open access
IRI. V. Rudenko
I. V. Rudenko
ABA. B. Bezrodnyi
A. B. Bezrodnyi
HMH. V. Mostbauer
H. V. Mostbauer
Myocardial bridges (MM) are common congenital anomaly of the coronary arteries (CA) with the location of a separate bundle of myocardial muscle fibers over any epicardial vessel, most often over the middle segment of the left anterior descending coronary artery (LAD). In most patients, MM has a benign course, though in 25% of cases, it can cause stable or unstable angina, myocardial infarction with non‑obstructive CA (MINOCA), paroxysmal rhythm disturbances, and sudden cardiac death. The pathophysiological mechanisms of the development of fatal and non‑fatal cardiovascular events in such patients are heterogeneous and usually complex. They may include mechanical obstruction of blood flow, violation of diastolic relaxation of the CA, local hemodynamic changes in the tunnelled segment, endothelial dysfunction, vasospasm, damage to the atherosclerotic plaque located in the MM zone, and spontaneous dissection of the CA. The purpose of our article was to present and discuss a clinical case of the development of MINOCA and potentially fatal ventricular arrhythmia in a 34‑year‑old man during competitive sports caused by MM in the LAD. MM was detected by invasive angiography. The diagnosis of MINOCA was established according to the criteria of the 4th universal definition of MI (clinical signs, ECG data, laboratory markers of myocardial damage). However, according to magnetic resonance imaging (MRI) of the heart 3 days after the onset of the disease, no inflammatory process, ischemic damage to the myocardium, and volume formations were found. At the same time, dilatation and hypertrophy of the left ventricle and myocardium fibrosis of non‑ischemic origin were present. There is currently no generally accepted algorithm for examining a patient with MM. Because of the heterogeneity of the pathophysiological mechanisms of myocardial ischemia in this cohort of patients, it is suggested to use invasive and non‑invasive angiography, invasive methods of intracoronary imaging, Doppler assessment of coronary blood flow, and provocative stress tests to detect vasospasm.

27 September 2023 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
HMH.V. Mostbauer
H.V. Mostbauer
TKT.A. Karasevska
T.A. Karasevska
LAL.P. Antonenko
L.P. Antonenko
IRIu.V. Rudenko
Iu.V. Rudenko
ABA.B. Bezrodnyi
A.B. Bezrodnyi
Background. Osteoporosis is actually today's problem, as it affects the quality and length of life, and increases the risk of fragility fractures, which leads to significant medical, social, and economic problems. One of the reasons for the development of secondary osteoporosis is the use of vitamin K and new oral anticoagulants, the use of which is increasing. The purpose of this review was to analyze of literature data regarding the impact of oral anticoagulants on the bone state, the risk of osteoporosis and its complications in order to improve the awareness of doctors of various specialties. Materials and methods. The lite­rature review was carried out based on the analysis of scientometric databases PubMed, Google Scholar, and Scopus using the keywords “vitamin K antagonists”; “warfarin; “osteoporosis”; “osteoporotic fracture”; “non-vitamin K antagonist oral anticoagulants”; “systematic review” for the period 2013-2023, but it did not exclude key works that were published earlier. The search was performed by two independent authors. 160 sources were selec­ted for analysis, of which 53 were used that met the search criteria. ­Results. The ana­lysis of researches showed that the effects of vitamin K antagonists and new oral anticoagulants on bone and the risk of fragility fractures are controversial. Nevertheless, the new oral anticoagulants in comparison to vitamin K antagonists seem to have a less negative effect on bone and the lowest risk of fragility fractures. The mechanism of such influence is still under examination. Conclusions. Most studies have demonstrated the adverse effects of vitamin K antagonists on bone health. A lower risk of fractures was observed with new oral anticoagulants than with vitamin K antagonists, in particular, warfarin. Taking into account the analyzed data of the literature, it is recommended to also assess the risk of fragility fractures when prescribing vitamin K antagonists or new oral anticoagulants.